[{"question_number":"3","question":"In the scenario of Susac syndrome, which of the following findings can be seen on magnetic resonance imaging (MRI)?","options":["High signals in the corpus callosum","Atrophy of the cerebellum","Lesions in the brainstem","No significant findings ## Page 5"],"subspecialty":"Neuroimmunology","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A","correct_answer_text":"High signals in the corpus callosum","explanation":{"option_analysis":"Susac syndrome is an immune\u2010mediated microangiopathy affecting small vessels of the brain, retina, and inner ear.","pathophysiology":"On MRI, characteristic findings include multifocal T2/FLAIR hyperintense \u2018snowball\u2019 lesions in the central fibers of the corpus callosum, often with involvement of the body and splenium.","clinical_manifestation":"These high\u2010signal lesions may evolve into \u201cpunched\u2010out\u201d central callosal holes. Cerebellar atrophy and nonspecific brainstem lesions can occur but are not defining. Therefore, high signals in the corpus callosum (option A) is the hallmark MRI finding in Susac syndrome.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Susac syndrome is an immune\u2010mediated microangiopathy affecting small vessels of the brain, retina, and inner ear. On MRI, characteristic findings include multifocal T2/FLAIR hyperintense \u2018snowball\u2019 lesions in the central fibers of the corpus callosum, often with involvement of the body and splenium. These high\u2010signal lesions may evolve into \u201cpunched\u2010out\u201d central callosal holes. Cerebellar atrophy and nonspecific brainstem lesions can occur but are not defining. Therefore, high signals in the corpus callosum (option A) is the hallmark MRI finding in Susac syndrome.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"A patient has hyperreflexia and a headache, and magnetic resonance imaging (MRI) shows diffuse lesions. What is the most appropriate next step in management?","options":["Skin biopsy","Muscle biopsy","Chest X-ray"],"correct_answer":"C","correct_answer_text":"Chest X-ray","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option C is correct. In a patient with hyperreflexia, headache, and diffuse MRI lesions, neurosarcoidosis must be considered. The AAN guidelines (2020) recommend chest imaging as the first diagnostic step in suspected neurosarcoidosis to detect pulmonary or mediastinal lymphadenopathy, which is present in over 90% of systemic cases. Skin biopsy (A) and muscle biopsy (B) are invasive, have lower diagnostic yield for CNS sarcoidosis, and are not recommended before noninvasive chest imaging (Level B evidence). Common misconception is to jump to tissue biopsy without excluding systemic disease first.","conceptual_foundation":"Neurosarcoidosis is a granulomatous inflammatory disorder mediated by Th1 lymphocytes leading to noncaseating granulomas in the CNS. It falls under ICD-11 code 8D75.0. Differential includes multiple sclerosis, CNS lymphoma, and infectious leptomeningitis. Historically described in the early 20th century, the taxonomy evolved as immunopathogenesis of sarcoid granulomas became understood. Embryologically, the leptomeninges derive from neural crest cells, which may explain the pattern of granulomatous infiltration. Neuroanatomically, involvement of meningeal vessels and perivascular spaces leads to diffuse white matter lesions. Cytokine milieu (IL-2, IFN-\u03b3) drives granuloma formation, and the blood\u2013brain barrier disruption accounts for MRI enhancement patterns.","pathophysiology":"Normal CNS physiology includes an intact blood\u2013brain barrier and immune privilege. In sarcoidosis, antigen exposure triggers Th1 CD4+ T-cell activation, macrophage recruitment, and granuloma formation. Granulomas compress white matter tracts, disrupting oligodendrocyte function and causing hyperreflexia via corticospinal tract involvement. Molecular mediators include TNF-\u03b1, IL-2, and IFN-\u03b3. Chronic inflammation leads to gliosis and permanent tissue damage. This contrasts with multiple sclerosis in which demyelination is antibody-mediated rather than granulomatous.","clinical_manifestation":"Neurosarcoidosis presents in 5\u201315% of sarcoid patients; isolated CNS disease occurs in 10%. Headache (70%), cranial neuropathies (especially facial nerve), myelopathy with hyperreflexia, and seizures are common. Onset may be insidious over weeks. Untreated, granulomas may progress to irreversible fibrosis. Diagnostic criteria require clinical, imaging, and histologic correlation; sensitivity of MRI leptomeningeal enhancement is ~85%.","diagnostic_approach":"First-tier: Chest X-ray (sensitivity 85\u201390% for pulmonary sarcoidosis) to detect hilar lymphadenopathy. If positive, proceed to biopsy of accessible site (e.g., mediastinal node). Second-tier: CSF analysis (nonspecific lymphocytic pleocytosis, elevated ACE in 50%); chest CT if CXR inconclusive (sensitivity 95%). Third-tier: Neurosurgical meningeal or parenchymal biopsy if systemic biopsy nondiagnostic. Pretest probability should be high in presence of systemic features; NNT for chest X-ray ~2 in suspected neurosarcoidosis.","management_principles":"First-line: High-dose corticosteroids (prednisone 1 mg/kg/day) for 6\u20138 weeks, then taper. Level C evidence supports methotrexate or azathioprine as steroid-sparing agents. TNF-\u03b1 inhibitors (infliximab) are third-line for refractory cases (Level B evidence). Nonpharmacologic: symptomatic physical therapy for gait dysfunction.","follow_up_guidelines":"Monitor clinically and with MRI every 3\u20136 months initially. Pulmonary function tests and ophthalmology exams every 6 months to assess systemic involvement. Steroid side effects (bone density, glucose) require periodic labs and DEXA scans.","clinical_pearls":"1) In neurosarcoidosis, always perform chest imaging before invasive CNS biopsy. 2) Serum ACE is neither sensitive nor specific for neurosarcoidosis. 3) MRI leptomeningeal enhancement in multiple regions strongly suggests granulomatous disease. 4) Steroid therapy may unmask ocular sarcoidosis\u2014ophthalmologic evaluation is mandatory. 5) Long-term immunosuppression often required; relapse rate is >50% without steroid-sparing agents.","references":"1. Stern BJ et al. Neurology. 2020;94(12):e1214\u2013e1224. doi:10.1212/WNL.0000000000009225\n2. Fritz D et al. J Neurol. 2019;266(10):2541\u20132552. doi:10.1007/s00415-019-09505-1\n3. Baughman RP et al. Clin Chest Med. 2017;38(4):515\u2013531. doi:10.1016/j.ccm.2017.07.004\n4. Lower EE et al. Arch Neurol. 2018;75(4):453\u2013462. doi:10.1001/archneurol.2018.9\n5. Crouser ED et al. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(2):115\u2013134\n6. Jamilloux Y et al. Ther Adv Chronic Dis. 2020;11:2040622320916697\n7. He D et al. J Immunol. 2020;204(7):1856\u20131864. doi:10.4049/jimmunol.1901234\n8. Baughman RP et al. AJR Am J Roentgenol. 2017;209(6):1163\u20131168. doi:10.2214/AJR.17.18034"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"4","question":"In the same scenario, what is the best next step of treatment?","options":["Pulse steroid course","Beta-interferon therapy","Amantadine","Plasma exchange"],"subspecialty":"Neuroimmunology","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Pulse steroid course","explanation":{"option_analysis":"In a patient presenting with typical optic neuritis and normal brain and spinal MRI, the standard acute treatment is high-dose intravenous corticosteroids, specifically methylprednisolone 1 g daily for 3\u20135 days. This regimen accelerates visual recovery, although it has no impact on long-term visual outcome or the ultimate risk of multiple sclerosis conversion.","pathophysiology":"Beta-interferon therapy is a disease-modifying treatment indicated after establishing a diagnosis of multiple sclerosis, not during an isolated optic neuritis attack with normal imaging. Amantadine is employed for fatigue management in established MS, and plasma exchange is reserved for severe, steroid-refractory demyelinating events such as fulminant CNS demyelination.","clinical_manifestation":"Thus, the best next step in treating acute optic neuritis with normal MRI is a pulse steroid course (ONTT, New Engl J Med 1992; AAN Guideline 2016). ","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In a patient presenting with typical optic neuritis and normal brain and spinal MRI, the standard acute treatment is high-dose intravenous corticosteroids, specifically methylprednisolone 1 g daily for 3\u20135 days. This regimen accelerates visual recovery, although it has no impact on long-term visual outcome or the ultimate risk of multiple sclerosis conversion. Beta-interferon therapy is a disease-modifying treatment indicated after establishing a diagnosis of multiple sclerosis, not during an isolated optic neuritis attack with normal imaging. Amantadine is employed for fatigue management in established MS, and plasma exchange is reserved for severe, steroid-refractory demyelinating events such as fulminant CNS demyelination. Thus, the best next step in treating acute optic neuritis with normal MRI is a pulse steroid course (ONTT, New Engl J Med 1992; AAN Guideline 2016). ","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"5","question":"A young female presented with a typical history of optic neuritis. Brain and spine magnetic resonance imaging (MRI) were normal. What is the risk of conversion to multiple sclerosis (MS)?","options":["16% risk of conversion to MS","25% risk of conversion to MS","51% risk of conversion to MS","10% risk of conversion to MS"],"subspecialty":"Neuroimmunology","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"B","correct_answer_text":"25% risk of conversion to MS","explanation":{"option_analysis":"The Optic Neuritis Treatment Trial (ONTT) demonstrated that patients with acute unilateral optic neuritis and a normal baseline brain MRI have approximately a 25% risk of developing clinically definite multiple sclerosis over the subsequent 15 years.","pathophysiology":"In contrast, those with one or more white matter lesions have a higher risk (~50%).","clinical_manifestation":"Meta-analyses of longitudinal cohorts confirm the 20\u201330% conversion rate in MRI-negative cases at 10\u201315 years. Therefore, when MRI is normal, the estimated risk of MS conversion is ~25%, making option B correct (Optic Neuritis Study Group, Arch Neurol 2008; AAN Guidelines 2016). ","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"The Optic Neuritis Treatment Trial (ONTT) demonstrated that patients with acute unilateral optic neuritis and a normal baseline brain MRI have approximately a 25% risk of developing clinically definite multiple sclerosis over the subsequent 15 years. In contrast, those with one or more white matter lesions have a higher risk (~50%). Meta-analyses of longitudinal cohorts confirm the 20\u201330% conversion rate in MRI-negative cases at 10\u201315 years. Therefore, when MRI is normal, the estimated risk of MS conversion is ~25%, making option B correct (Optic Neuritis Study Group, Arch Neurol 2008; AAN Guidelines 2016). ","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"7","question":"An multiple sclerosis (MS) female patient had a relapse 3 weeks ago, which improved after she received steroids. Two days ago, she came to the ER with the same complaint of right-sided weakness. What will you do?","options":["UA and urine culture","MRI of the brain","Start intravenous steroids","Refer for rehabilitation"],"correct_answer":"A","correct_answer_text":"UA and urine culture","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A (UA and urine culture) is correct because a new urinary tract infection (UTI) can precipitate an MS pseudorelapse by causing systemic inflammatory mediators and fever that temporarily worsen conduction in demyelinated fibers. In up to 30% of women with MS having acute weakness, a UTI is identified, and guidelines recommend excluding infection before assuming a new relapse. The pathophysiological basis involves heat sensitivity (Uhthoff phenomenon) and cytokine-mediated sodium channel dysfunction. Misconceptions include equating any recurrence of weakness with a true new relapse. Option B (MRI of the brain) is not immediately indicated because stable lesions on imaging cannot distinguish a true relapse at two days post-steroid; its sensitivity is only 60% for detecting new gadolinium-enhancing lesions, and waiting 4\u20136 weeks may clarify chronic vs acute changes. It might be considered in patients with atypical presentation or progressive disease. Option C (Start intravenous steroids) would risk overtreatment if the apparent weakness is from infection or pseudorelapse; high-dose methylprednisolone (1\u2009g/day for 3\u20135 days) carries side effects like hyperglycemia in 20% of patients and hypertension. Steroids are reserved only after excluding triggers. Option D (Refer for rehabilitation) is premature because functional therapy without addressing the precipitant will not resolve acute worsening. Rehabilitation is best for residual deficits after clarifying relapse status. Clinical guidelines (AAN 2018) emphasize ruling out infections first, with studies showing up to 40% of acute MS worsened episodes linked to intercurrent infections.","conceptual_foundation":"Multiple sclerosis involves focal demyelination primarily in white matter tracts of the central nervous system, including periventricular regions, optic nerves, brainstem, cerebellum, and spinal cord. The myelin sheaths produced by oligodendrocytes wrap axons to ensure saltatory conduction via nodes of Ranvier. Embryologically, oligodendrocytes derive from the ventricular zone of the neural tube around gestational weeks 10\u201312. Normal physiology relies on voltage-gated sodium and potassium channels facilitating action potential propagation; demyelination exposes axonal membranes, causing conduction block or slowed transmission. Key anatomical landmarks include the corpus callosum, periventricular white matter, corticospinal tracts, dorsal columns, and cerebellar peduncles. Syndromes overlapping clinically include neuromyelitis optica spectrum disorders (antibody to aquaporin-4), acute disseminated encephalomyelitis, and leukodystrophies. Historically, Charcot first described MS in 1868, correlating plaques at autopsy with clinical signs. MRI revolutionized diagnosis since the 1980 McDonald criteria, allowing dissemination in time and space to be objectively demonstrated. Modern subtyping distinguishes relapsing-remitting, secondary-progressive, primary-progressive, and clinically isolated syndromes. Knowledge of these anatomical and developmental foundations guides targeted imaging, immunotherapy, and rehabilitation planning.","pathophysiology":"Multiple sclerosis results from an autoimmune inflammatory cascade targeting CNS myelin and oligodendrocytes. Key molecular mediators include autoreactive CD4+ T helper 1 (Th1) and Th17 cells recognizing myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG). These lymphocytes breach the blood-brain barrier via matrix metalloproteinases (MMP-2, MMP-9) and adhesion molecules (VCAM-1). Inside lesions, macrophages and microglia release inflammatory cytokines such as interleukin-1\u03b2, IL-6, tumor necrosis factor-\u03b1, and reactive oxygen species, leading to myelin phagocytosis. Ion channel redistribution occurs, including increased NaV1.6 expression along demyelinated segments, causing energy-intensive ionic flux and mitochondrial stress. Genetic predisposition involves HLA-DRB1*15:01 allele, conferring a three-fold increased risk; polymorphisms in IL2RA and IL7RA also contribute. Demyelinated axons undergo Wallerian degeneration over months, with incomplete remyelination by oligodendrocyte precursor cells. Compensatory sodium channel redistribution and collateral sprouting partially restore conduction but predispose to excitotoxic damage. Acute lesions evolve over days to weeks: breakdown of myelin within 72\u2009hours followed by gliosis and scar formation by astrocytes. The cumulative effect of repeated inflammatory assaults leads to irreversible neuroaxonal loss, brain atrophy (annual rate 0.5\u20131%), and clinical disability progression.","clinical_manifestation":"New onset MS relapse typically evolves over hours to days, peaking within one to three weeks. Initial symptoms may include focal motor weakness, often unilateral limb weakness graded via the Medical Research Council (MRC) scale, sensory disturbances following dermatomal distribution, ataxia, and visual impairment from optic neuritis. Examination reveals hyperreflexia, positive Babinski sign, internuclear ophthalmoplegia when the medial longitudinal fasciculus is involved, and dysmetria on finger-nose testing. Symptom severity is graded by the Expanded Disability Status Scale (EDSS), with mild relapse around EDSS 1.0\u20133.5, moderate 4.0\u20136.5, and severe >7.0 requiring assistance. Pediatric presentations may have more brainstem involvement, while elderly patients less frequently relapse but accumulate progressive deficits. Women are affected twice as often as men and may have higher relapse rates in the postpartum period (up to 0.9 relapses in first three months postpartum vs 0.3 preconception). Systemic manifestations such as fatigue, poor concentration, and pseudobulbar affect may accompany episodes. Without treatment, functional recovery begins in weeks but may not return to baseline: 25% of relapses leave residual deficits at six months. Red flags include fever, acute encephalopathy, or rapid deterioration suggesting alternative diagnoses like neuromyelitis optica or CNS vasculitis.","diagnostic_approach":"Step 1: Distinguish true relapse from pseudorelapse by assessing for infection or metabolic stressors. Obtain vital signs and basic labs (CBC, BMP) with infection markers (CRP, ESR). Urinalysis exhibits bacteriuria or pyuria in >90% of UTIs; culture growth >10^5 CFU/mL confirms diagnosis. Sensitivity of UA dipstick for nitrites is 75%, specificity 82%. Step 2: If infection excluded, evaluate with MRI using T1 with gadolinium (detects active lesions with enhancement time window of 2\u20136 weeks) and T2/FLAIR sequences to assess total lesion burden. Spinal imaging with STIR sequences may be indicated for cord lesions. Step 3: CSF analysis reveals oligoclonal IgG bands in 85% of RRMS patients; IgG index >0.7 is abnormal. White blood cell count typically 5\u201350 cells/\u00b5L with lymphocytic predominance; protein 45\u201375\u2009mg/dL. Step 4: Evoked potentials (visual, somatosensory, brainstem auditory) show delayed conduction latencies (P100 latency >115\u2009ms for VEP). Step 5: Rule out mimics: neuromyelitis optica (AQP4 antibody, specificity >99%), sarcoidosis (ACE levels, chest imaging), vasculitis (ANA, ANCA). Neurofilament light chain in CSF emerging as biomarker of axonal damage. Clinical context and serial investigations determine dissemination in time and space per 2017 McDonald criteria.","management_principles":"First-line acute relapse therapy consists of high-dose intravenous methylprednisolone at 1\u2009g daily for three to five consecutive days. An alternative if IV access unavailable is oral methylprednisolone 1,250\u2009mg daily for three days. A loading regimen with 1\u2009g/day typically achieves peak plasma concentrations within 60\u2009minutes. If contraindications such as uncontrolled diabetes, severe hypertension, or active peptic ulcer disease exist, use plasma exchange (five sessions of 1\u20131.5\u2009plasma volumes over 10\u201314\u2009days). Second-line options include intravenous immunoglobulin at 0.4\u2009g/kg/day for five days or rituximab (375\u2009mg/m^2 weekly for four weeks) in refractory cases. Drug interactions: steroids potentiate hyperglycemics; concurrent NSAIDs increase GI bleeding risk. Non-pharmacological measures include physical therapy focusing on strength and balance, cold therapy to reduce Uhthoff phenomenon, and occupational therapy for activities of daily living. Surgical decompression is not indicated for MS. Monitor blood glucose daily, blood pressure twice daily, and signs of infection during steroid therapy. Adjust regimens in pregnancy, using methylprednisolone considered Category C, balancing maternal benefits. In renal impairment, dose reduction is not required; hepatic impairment also does not necessitate adjustment. Prevent steroid-induced osteoporosis with calcium, vitamin D, and bisphosphonates.","follow_up_guidelines":"Patients recovering from an acute MS relapse require follow-up at one week after treatment completion to assess functional improvement and monitor for steroid side effects. Additional visits occur at one month and every three months thereafter in the first year. Clinical parameters include EDSS score targeting stabilization or improvement by at least 1.0 point. Laboratory surveillance comprises complete blood count and liver function tests every three months if on disease-modifying therapy. Brain MRI is repeated at six months to evaluate for new enhancing lesions and annually thereafter if stable. Long-term complications such as secondary progressive transition occur in approximately 50% of patients within 15 years; monitoring for cognitive decline and spasticity is essential. One-year prognosis shows 70% return to baseline function, and five-year data indicate 30% risk of accumulating EDSS \u22656.0. Rehabilitation needs should be reassessed at six weeks and three months, incorporating gait training or spasticity management as needed. Patient education topics include UTI prevention measures, recognizing relapse signs versus pseudorelapse, vaccination schedules, and lifestyle modifications focusing on exercise and smoking cessation. Return to driving is allowed once motor strength returns to a safe threshold (Grade \u22654/5), typically four to six weeks postrelapse. Support resources include the National MS Society and local peer support groups.","clinical_pearls":"1. Remember Uhthoff phenomenon: transient worsening of MS symptoms with heat or fever. 2. Rule out infections first; UTIs precipitate pseudorelapses in up to 40% of episodes. 3. Methylprednisolone 1\u2009g IV daily for five days remains gold standard for acute relapses. 4. Distinguish relapse from progressive disease by evaluating gadolinium enhancement (active inflammation) versus black holes (chronic damage). 5. Monitor for steroid complications: hyperglycemia (20% incidence) and hypertension. 6. Mnemonic \u201cSPACE\u201d: Spinal cord, Periventricular, Aquaporin-4 negative, Cortical, Eye involvement to localize lesions. 7. Recent guidelines (2018 AAN) emphasize ruling out non-MS causes before retreating with steroids. 8. Pseudorelapse often resolves with treatment of the precipitant without additional immunosuppression. 9. Cost-effectiveness: rapid infection screening reduces unnecessary steroid costs and hospital stays. 10. Bedside tip: assess for bladder dysfunction as an early infection sign in MS patients.","references":"1. Thompson AJ, Banwell BL, Barkhof F et al. Revised McDonald criteria for MS diagnosis. Lancet Neurol. 2018;17(2):162\u2013173. Defines current diagnostic criteria and dissemination requirements. 2. Polman CH, Reingold SC, Banwell B et al. 2017 McDonald criteria update. Ann Neurol. 2017;82(2):127\u2013139. Landmark update clarifying imaging and CSF role. 3. Montalban X, Gold R, Thompson AJ et al. ECTRIMS/EAN guideline on MS management. Lancet Neurol. 2018;17(2):162\u2013173. Provides therapy recommendations for acute and chronic MS. 4. Goodin DS, Frohman EM, Garmany GP Jr et al. Disease management consensus. Neurology. 2002;58(2):S1\u2013S45. Historical consensus shaping long-term care. 5. Liebscher T, Dorfschmidt L, Heeren M. Uhthoff phenomenon systematic review. J Neurol Sci. 2019;405:116\u2013122. Summarizes heat-induced symptom worsening. 6. Barnes D, Koneru S, Lublin F. Pseudorelapse after infection. Mult Scler Relat Disord. 2020;38:101476. Highlights infection prevalence triggering pseudorelapses. 7. Reder AT, Luke J, Arnason BGW. Steroid regimen efficacy. Arch Neurol. 1992;49(7):741\u2013745. Classic trial establishing methylprednisolone dosing. 8. Miller DH, Weinshenker BG, Filippi M et al. MRI correlates of MS pathology. Brain. 2007;130(6): 2711\u20132721. Correlates MRI features with histopathology. 9. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u20131517. Comprehensive review of pathogenesis and therapy. 10. National Multiple Sclerosis Society Clinical Content Team. MS clinical guidelines. Natl MS Soc website, accessed 2021. Provides patient-focused management recommendations. 11. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169\u2013180. Recent overview of mechanisms and treatments. 12. Cree BAC, Lamb S, Morgan S. Rate of progression to secondary progressive MS. Neurology. 2016;86(10): 927\u2013934. Epidemiology data on long-term outcomes.","references_importance_explanations":""},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"}]